Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients. (3rd October 2018)

• Record Type: Journal Article
• Authors: Kono, Takashi; Ueda, Tsutomu; Takumida, Masaya; Furuie, Hiromi; Hamamoto, Takao; Takeno, Sachio; Hirakawa, Katsuhiro
• Is Part Of: Acta oto-laryngologica. Volume 138:Number 10(2018)
• Page Start: 921
• Page End: 925
• Publication Date: 2018-10-03
• Subjects: Head and neck cancer -- CINV -- dexamethasone -- HEC -- aprepitant -- fosaprepitant; Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.1080/00016489.2018.1482423
• Languages: English
• ISSNs: 0001-6489

Abstract

Abstract: Objective: To determine if a lower dose of dexamethasone can be used in combination with fosaprepitant and palonosetron for cisplatin-induced nausea and vomiting in head and neck cancer patients, we conducted a single-center, two-arm, cross-over comparison study. Methods: Patients were randomly assigned to either standard dose dexamethasone group: intravenous 9.9 mg on day 1 and 6.6 mg on days 2–4 or low-dose dexamethasone group: intravenous 3.3 mg on days 1–4 for the first course and crossed over to the other treatment for the second course. The primary endpoint was complete response (CR) in the overall period. Results: Twenty-five patients were screened for the study and 22 were evaluable. Eleven patients were randomly assigned to the standard dose dexamethasone group and 12 patients to the low-dose dexamethasone group. The CR rate in the overall period was 86% in the standard dose group and 73% in the low-dose group, showing no significant difference ( p = .61). Conclusion: The efficacy of low-dose dexamethasone with fosaprepitant and palonosetron was not inferior to that of the standard dose dexamethasone in the highly emetogenic cisplatin-based treatment for head and neck cancer patients.